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Abstract
One of the more pressing issues in modern day health care is the nationwide heath care crisis
known as the opioid epidemic. The beginning of this literature review will focus on the history of
opioid use and early prescription rates, as well as the summary and definitions of the drugs
involved in the current opioid epidemic. The review then shifts to the pathophysiology of addiction
involving the activation of opioid receptors and opioid use disorder. The main focus of this
literature review is the societal impacts of the opioid epidemic, making special reference to the
economic burden and effects on Rural America. The conclusion of this review offers some insight
into possible solutions of combating the current opioid epidemic.
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INTRODUCTION
Current State of the Opioid Epidemic
Over the last two decades, opioid abuse and opioid related mortality rates have increased
dramatically to reach epidemic levels, leading to a public health care crisis in the United States.
This rise in mortality rates due to opioid overdoses can be described in three distinct waves. The
first wave began with a rise in prescriptions opioid overdose deaths due to an increase in
prescribing rates of opioids, both natural and semi-synthetic, in the 1990s (1). The second wave
began in 2010, with heroin being the main contributor to overdose deaths (1). The third and current
wave involves synthetic opioids, particularly those involving illicitly manufactured fentanyl (IMF)
(2, 3). The current IMF market continues to evolve, and now IMF is commonly found in
combination with heroin, prescription opioid pills, and cocaine (2, 3). This continual evolution
further contributes to the increasing mortality rates surrounding opioid overdoses and the current
heath care crisis known as the opioid epidemic (2, 3).

COMPONENTS OF THE OPIOID EPIDEMIC
History of Opioid Use and Prescription Rates
Morphine and heroin were naturally derived in the 1800s from the opium poppy, and were
recognized by their medicinal properties (4). These drugs, marketed towards physicians and
patients as a safe, efficient, and effective way to treat pain and minor ailments, were used liberally
with limited federal and pharmaceutical industry oversight to treat common ailments including
cough, diarrhea, anxiety and minor pain (4-6). In 1915 the Harrison Anti-Narcotic Act was
implemented with the intention to regulate opioid prescribing and administration practices (7).

Since the passage of the Anti-Narcotic Act, health care providers and patients informed of
the possible side effects of opioid use had similar concerns about developing addiction after being
placed on such drugs (8). In the 1980s however, attitudes towards opioid safety and painmanagement began to shift significantly (6). Opioids had previously been reserved only for severe
and impeding cancer pain and end-of-life care (6). However with shifting ideals regarding the
underutilization of pharmaceutical opioids, pain specialists along with patient advocacy
organizations began to raise awareness and bring attention to concerns regarding the inadequate
management and treatment of non-cancer pain (6).
The American Pain Society (APS) introduced an influential campaign regarding pain
assessment and management practices by physicians and healthcare persons, resulting in the
establishment of the “fifth vital sign”, and by the late 1990s, repeated monitoring and pain
intervention was imposed upon heath care providers (8). In 2001, The Joint Commissions set new
pain management standards, linking patient satisfaction and healthcare quality to pain control (6,
8). Opioid prescription rates were further influenced through training sessions and promotional
videos created, supported, and financed by large pharmaceutical companies targeted towards
physicians that inaccurately conveyed the danger and risk of addiction from opioid use as “less
than one percent” (9).
Opioid prescribing rates peaked in 2010 at 225 million prescriptions dispensed as a result
of the widespread marketing campaigns and increased attention on pain management practices
(10). Initially propelled by the increased consumption and accessibility of pharmaceutical opioids,
a rising amount of opioid overdoses associated with heroin and now illicitly manufactured fentanyl
and fentanyl analogs now fuels the current opioid epidemic (6).

Opioids and Opiates
Opioids refer to all natural, synthetic, or semi-synthetic
chemicals that interact with opioids receptors and reduce the intensity
of pain signaling (11). Opiates refer to opium alkaloids derived
directly from the naturally occurring opium poppy including but not
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used to treat acute to severe, chronic pain (12). The semi-synthetic
opioids include heroin, oxycodone and hydrocodone, while the
synthetic opioids include methadone and fentanyl (6, 11).
Fentanyl and Fentanyl Analogs
The fully synthetic opioid fentanyl was first synthesized by
Paul Janssen in 1960 with the justification that fentanyl would serve
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as a highly potent drug with claims of improved receptor specificity, and that compared to
morphine would possess a greater adverse effect profile (13). Fentanyl was first approved in the
United States by the FDA in 1972 as an option for the treatment of pain, and permitted only to be
used in combination with droperidol due to concerns about its
property of extreme potency (13, 14).

Despite these early

concerns about the potential dangers, fentanyl was still an
integral part in pain management of for chronic cancer patients
and cardiac anesthesia due to its ability to block the body’s
stress responses induced by surgical stimuli and to provide
cardiovascular stability during surgical procedures (13).

Figure 3. Chemical structure
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Up until the 1990s, clinical use of fentanyl was restricted to anesthesia. However,
developments and new formulations were created, leading to the introduction non-injectable
formulations including but not limited to fentanyl transdermal patches, sublingual tablets,
sublingual sprays, and nasal sprays (13). Due to knowledge of its high potency and high potential
for abuse, the United States DEA classified fentanyl and a number of other fentanyl analogs into
Schedule II of the Controlled Substance Act (13). Decades after its approval and classification,
fentanyl abuse reports were relatively low compared to other prescription opioids including
oxycodone and hydrocodone (13). Most of the early reports of fentanyl abuse were attributed to
abuse either by healthcare professionals that possessed easy access and occupational exposure to
fentanyl, or abuse of transdermal patches mainly by patients or persons with substance abuse
disorders (15). Prevalence rates concerning the non-medical use of FDA-approved fentanyl and
fentanyl analogs remained low.
Despite previous low prevalence rates, in the mid-2000s there was a significant increase in
overdose deaths due to illicitly manufactured fentanyl (IMF) (14). In 2006, the Centers for Disease
Control and Prevention (CDC) and the Drug Enforcement Administration (DEA) discovered that
most of the NFP involved in overdose deaths originated from NPF laced heroin or cocaine
intentionally sold as a street drug and for injection purposes (14, 16). The origin of this fentanyl
outbreak was attributed to and traced back to one single illegal clandestine laboratory that was
developing illicitly manufactured fentanyl; once this lab was shut down, overdose deaths attributed
to fentanyl and seizures of NFP promptly declined (13). In 2010 NPF-laced heroin and cocaine
re-emerged, and from 2012 to 2014 the number of NPF related deaths more than doubled (17).
The rise in circulating NPF has created a significant health crisis. Those exposed are typically

unaware the of addition of NPF, and subsequently are unaware of the alteration of their standard
heroin, cocaine, or prescription strength opioid pills (14).
Following the synthesis of fentanyl, numerous
fentanyl analogs with chemical structures similar to fentanyl
were developed for medical and veterinary use, including
but not limited to carfentanil (14). Figure 5 depicts the
timeline of events related to select fentanyl and fentanyl
analogs (14). Carfentanil first made an appearance in the US

Figure 4. Chemical structure depiction
of carfentanil. U.S. National Library
of Medicine. 2016.

heroin supply in 2016, with the first outbreak concerning occurring in the Midwest and
Appalachian region (14). During this outbreak, the DEA estimated for about 300 overdoses due to
consumption of this fentanyl analog (14). In 2016, the CDC estimated that heroin or a synthetic
opioid such as fentanyl was involved in over 80% of the opioid overdose deaths in 2016, and saw
a 100% increase in deaths due to synthetic opioids from 2015 to 2016 (18).

Figure 5. Timeline of select fentanyl events. Armenian et al. Neuropharmacology. 2018.

The current opioid epidemic with fentanyl as the main contributor has resulted from
multiple fradulent laboratories with locations worldwide (13). These laboratories manufacture
illicit NPF and other fentanyl analogs that would have eluded scheduling by the DEA until very
recently, but are now covered under a new derivative law to prevent prosecution evasion (13). The
presence and proliferation of fentanyl and fentanyl analogs in the illicit drug market has been a
result of several factors including profitability, availability, and the increasing amount of
restrictions concerning prescription opioids (14).

PATHOPHYSIOLOGY
Opioid Receptors and Fentanyl Pharmacology
Four types of opioid receptors have been identified to date: mu, delta, kappa, and opioid
receptor like-1, and these receptors are classified as G-protein coupled seven-transmembrane
signaling proteins (19, 20). Fentanyl, a fully synthetic lipophilic phenylpiperidine opioid, is a full
agonist of the mu-opioid receptor (13). This potent opioid produces its pharmacological effects via
activation of the mu opioid receptor, and exhibits lower affinity for opioid receptors delta and
kappa (13, 21). Fentanyl has a faster onset, shorter duration, and higher analgesic potency
compared to morphine (13). Through human and preclinical studies, it was determined that
fentanyl is 50 times more potent than morphine via intramuscular route, 150 times more potent via
subcutaneous route, and 400 times for potent when administered intravenously; most physicians
accept and report that compared to morphine, fentanyl is on average approximately 100 times more
potent (13).
Part of fentanyl’s enhanced analgesic properties can be attributed to its ability to rapidly
cross the blood brain barrier (13). The short duration and subsequent rapid decline of fentanyl

levels in the body is due to the redistribution to other tissues, rapid sequestration into body fat, and
in part due to activity of blood brain barrier P-glycoproteins involved in pumping fentanyl out of
the central nervous system (13, 22). The lipophilic and solubility properties of fentanyl impact not
only the clinical route of administration, but the pharmacology kinetics of its metabolism and
elimination within the body (13).
Fentanyl has been identified as a highly effective full agonist of the mu opioid receptor
(13). Previous evidence suggested that the primary action of opioid receptors within the nervous
system was opioid receptors positively coupling to potassium channels while negatively regulating
calcium channel (20). New findings suggest that opioid receptors exhibit effects on ion channel
regulation in addition to slower yet robust effects on signal transduction pathways (20).
Opioids most commonly used for the management of pain, such as morphine and fentanyl,
act on the mu opioid receptor (MOR) systems (20). Mu opioid receptors contain serine, threonine,
and tyrosine residues that are accessible to protein kinases, enabling the phosphorylation of the
receptor (20). MOR systems have a seven-transmembrane spanning helical domain that is
connected by extracellular and intracellular loops, and this receptor exhibits its effects through
interactions with inhibitory heterotrimeric G-protein (13). The interactions between the MOR and
heterotrimeric G proteins are responsible for the subsequent opioid related pharmacological
effects, including but not limited to euphoria and analgesia (13).
New studies also show that MOR can also produce G-protein independent signaling
through utilization of beta-arrestin complexes, and this arrestin signaling has been suggested to be
responsible for the respiratory depressive effects that opioids exhibit (13). It is well known that
fentanyl, similar to other opioids, yields subsequent respiratory depression primarily due to opioid
receptor activations in the pre-Bötzinger complex located in the ventral respiratory group in the

medulla (13). When in combination with other drugs of abuse or central nervous system
depressants, fentanyl is likely to engage additional harmful mechanisms, including cardiac
arrhythmias, which subsequently lead to mortality (13).
The existing knowledge gap of how fentanyl may contrast from other opioid drugs and
receptor agonists is predominantly due to the differences in fentanyl administration practices in
clinical settings and the self-administration by drug users for euphoric effects (13). What is known,
however, is that mu opioid receptor agonists elicit analgesic effects, are mood enhancers and cause
activation of dopamine reward pathways leading to the modulation of euphoria (20). These
unwanted side effects of opioid use are major contributing factors to the opioid dependence and
addiction.
Opioid Use Disorder (OUD)
Opioids biding to receptors in the CNS illicit euphoric and pain-relieving effects, and after
repeated use, dependence, tolerance, and opioid use disorder (OUD) may occur; each condition is
represented with distinctive phenomena and characteristics, and markedly distinctive clinical
symptoms and implications (6). Opioid tolerance and dependence includes anticipated and
phycological adaptions within the body occurring as a result of repeated significant doses of
pharmaceutical or illegal opioid substances (6). Dependence symptoms are not unique to opioids
and are characterized by signs and symptoms of withdrawal resulting from when the regular dose
being administered is reduced or stopped abruptly (23). Tolerance is characterized by a diminished
response to a substance as a result of frequent use, and often requires opioid users to increase doses
in order to achieve an equivalent analgesic response (23).
Opioid use disorder, unlike dependence and tolerance, is not an adaptive or anticipated
response to continual opioid exposure but is instead characterized by problematic patterns of

behavior including irrational and compulsive drug seeking and use despite the detrimental
consequences that accompany this behavior due to intense cravings (24). Environmental, social,
and genetic factors contribute to the development of OUD, and make some patients more
susceptible than others (6). OUD is a complex disease that is currently not fully understood by
researchers

and

clinicians;

addiction, a disease of the brain
more commonly understood, results
from

recurrent

exposure

to

substances that alter the brain’s
structure and function, eventually
contributing to the symptoms and
characteristics of OUD, particularly
drug seeking behavior (25).
Opioid use disorder can be
defined as a pattern opioid use that
is associated with a wide range of
physical, mental, social and legal problems; these problems are also associated with increase
mortality, clinically significant distress or impairment. The diagnostic criteria for OUD are
outlined in Table 1, where an opioid use disorder is the repeated occurrence of 2 or more of the 11
problems within a 12-month period (26). Throughout the clinical course of opioid use disorder,
periods of exacerbation and remission occur, however the underlying susceptibility to opioid
addiction never disappears. This pattern of OUD is similar to other chronic relapsing conditions,

such as heart disease and diabetes, where complete control of symptoms can be difficult to achieve
and patient adherence to treatment is ever evolving and often incomplete (27).
Individuals suffering from opioid use disorder also have increased risk of comorbid
conditions, often coinciding with lack of regular health care and the undertreatment of other
illnesses (28). The most common comorbid conditions associated with OUD include hepatitis C
and HIV (28). HIV management can be challenging due to the multifactorial nature of the disease,
including social, physical and economic factors which may disrupt the required continuum of care
(29). Effective treatment are available for treatment of hepatitis C but are historically expensive
and under prescribed, specifically when pertaining to persons with opioid use disorder (30).
Individuals suffering from OUD, particularly those who inject drugs, are more prone and at
increased risk of developing infections, both local and systemic (29). Neonatal abstinence
syndrome is another notable medical consequence of opioid use disorder, where neonates born to
mothers exposed to opioids during the duration of their pregnancy can experience withdrawal
symptoms in the first few days of life (31).
Treatment of Opioid Use Disorders
In most cases of opioid use disorder, persons affected present with acute symptoms and in
some cases it presents as early opioid withdrawal (28). The period of acute withdrawal symptoms
experienced by affected persons depends on the degree or severity of physical dependence and the
specific opioid from which the persons with OUD is withdrawing (28). Shorter periods of acute
withdrawal symptoms – typically 7 to 10 days – are more closely associated with short-acting
opioids, while longer acting opioids are associated with longer periods of withdrawal, lasting up
to 14 days or longer (28). Once the phase of acute withdrawal is complete, persons may enter a
period of prolonged withdrawal, characterizes by insomnia, hyperalgesia, dysphoria and cravings

(28). The symptoms experienced during both acute and prolonged withdrawal may be a powerful
trigger for relapse, but also can be managed symptomatically and can be used as an opportunity
for OUD patients to enter treatment (28). The sudden cessation of opioids after long-term use may
produce symptoms that result from physiological changes that occurred during extended period of
drug use (27). These symptoms may be relieved and managed via medication, and then gradually
reduced in order to allow persons suffering from OUD to adjust to the absence of opioids (27).
Three FDA-approved medications – methadone, buprenorphine, and naltrexone – are
currently used for the treatment of withdrawal for persons diagnosed with opioid use disorder (6).
Methadone and buprenorphine are opioid receptor agonists that provide consistent systemic drug
levels due to their long-acting properties (32). This consistent systemic drug level activity has been
shown to reduce opioid cravings and prevent withdrawal symptoms, thus making these
medications favorable treatments for OUD (27, 32). Naltrexone acts as an opioid receptor
antagonist, and therefore is able to block the effects of opioids and can help prevent relapse when
taken as directed (6).
Methadone is an oral MOR agonist with a half-life of 15 to 40 hours, and its use in
maintenance treatment for persons suffering with OUD has been widely used (27). In the United
States, methadone maintenance treatment is only offered through licensed and approved clinics
and occurs in approximately three phases (27). The induction and early stabilization phase involve
a low dose of methadone administration followed by gradual increases which require daily
monitoring; the late stabilization phase involves increased doses as tolerance increase and craving
decreases (33). Finally, the maintenance phase involved doses of methadone administrated to
avoid drug-related euphoria, sedation or cravings (33). Methadone may result in overdoses when
given at doses above tolerance level or when used in conjunction with other CNS depressants (28).

Buprenorphine is an analgesic that is available as a monotherapy in sublingual from or in
combination with naloxone, and is a partial MOR agonist, an agonist of delta and opioid-like
receptor-1, and an antagonist of kappa opioid receptors; this drug has a long half-life of 3 hours,
which makes it useful and advantageous in OUD treatment, but can be lethal and lead to overdose
when used in conjunction with other CNS depressants (27). A 1 month extended release injection
was approved by the FDA in 2017,

and another 1-month and 1-week extended release

formulations are currently being review by the FDA (29). The number of patients that physicians
who are approved to prescribe buprenorphine was increased from 30 to 275 patients in 2016, thus
increasing access to treatment (27).
Naltrexone is administered to patients in order to block the effects of opioids, resulting in
the maintenance of opioid abstinence (34). As an oral medication, naltrexone is required to be
taken daily with effects lasting 24 to 36 hours, or monthly as an extended release injectable
medication (27). Adherence to daily dose administration of naltrexone is challenging, and efficacy
studies concerning this OUD treatment drug have been contradictory to the improvement of
patients and the superiority of the oral route to monthly injections (35, 36). Another concern with
patients who use naltrexone for OUD treatment is the increased danger of overdosing due to the
discontinuation of treatment using naltrexone only and the resumption of opioid use (37).
By itself, medically supervised withdrawal is usually not sufficient to produce long-term
recovery and may increase the risk of overdosing in patients who have lost their tolerance to
opioids (30). Treatment of OUD with medication is most effective when administered as a part of
a cognitive behavioral approach (27). Patients are also encouraged to minimize relapses through
the combination of education, motivational enhancement, and by encouraging lifestyle changes
that diminish drug-related problems; persons experiencing substance-abuse disorders are also

encouraged to utilize self-help programs such as Narcotics Anonymous (38). This combination of
treatment options encourages patients to change how they think about the effects that opioids have
on their lives and to recognize that change is possible (38).

SOCIETAL IMPACTS
Impact on Rural America
Opioid-related mortality rates have continued to increase resulting in a nationwide health
concern in the United States. Despite the common belief the “addiction does not discriminate”,
there is substantial geographic variation in drug related mortality rates across the United States
(39). Opioid-related mortalities, inpatient hospital state, and emergency department visits occur at
higher rates in some predominantly rural states such as Maine, Kentucky, and West Virginia (40).
However, rates of other largely rural state including Iowa, Nebraska, and South Dakota are among
the lowest (40).
Rural areas, when compared to large urban areas, have generally been overlooked by the
media, researchers, and national politicians (40). Due to this disparity of coverage, most national
studies place their focus on urban areas, and the geographic diversity of the opioid epidemic is
obscured (40). Inconsistencies also exist in literature pertaining to the differences between rural
and urban opioid use disorders and mortality, and may be a result the national trends distorting
important regional and state to state differences due to inconsistent data and coverage (41).
In a study completed by Rigg et al, data from the CDC was utilized in order to avoid
inconsistencies and to describe the geographic heterogeneity that exists when determining opioidrelated mortality trends and occurrences (40). The authors of this study determined that opioidrelated mortalities were the highest overall in urban counties and the lowest the most rural

communities (40). However, the sharpest increase in opioid-related mortalities occurred in more
rural than urban areas over the past two decades (40).
Variation also exists within
rural areas of each state. Figure 6
depicts

opioid-related

mortality

rates taking into account only the
rural counties within each state for
2012-2016 (40). As seen in Figure 6,
opioid-related mortalities are the
highest in rural central Appalachia,

Figure 6. Rural opioid-related mortality rates, by state, 2012-2016.
Rates are age adjusted deaths per 100,000 population. Rigg et al.
International Journey of Drug Policy. 2018.

New England, New Mexico, and Utah; rural counties in West Virginia contributed the highest
occurrence of opioid-related mortality rates (40). Largely rural states such as Nebraska, South
Dakota, and North Dakota possess low opioid-related mortality rates (40).
Another downfall when determining the geographic differences of the opioid epidemic is
the failure to distinguish between the types of opioids involved in opioid-related mortalities. The
effectiveness of preventative methods and reduction of opioid overdoses may differ depending on
the nature of opioid involved (40). A larger share of rural opioid-related deaths are caused by
prescription opioids rather than heroin or synthetic opioids (40). It is however important to note
that since 2013, synthetic opioids – primarily illicitly manufactured fentanyl – have contributed to
a larger proportion of rural opioid-related mortalities than heroin (40). Using data collected from
the CDC, the percentage of all rural opioid-related mortalities age-adjusted per 100,000 population
is depicted in Figure 7 (40). Rigg et al worked to determine factors that contribute to the geographic
heterogeneity of the opioid epidemic and to the higher prevalence of opioid-related mortality in

some of the hardest-hit rural
counties in the United States; they
determined three major groups of
factors the likely contributed to
the diverse distribution opioidrelated

mortality

rates:

infrastructural, demographic or
socioeconomic, and social (40).

Figure 7. Percentage of all rural drug overdose deaths involving heroin,
prescription opioids, synthetic opioids, and unspecified opioids 19992016. Rigg et al. International Journey of Drug Policy. 2018.

Infrastructural factors mentioned by Rigg et al include methods of treatment for persons
suffering with opioid-related addiction including but not limited to drug treatment programs and
providers, medication assisted treatment (MATs), and the emergence of synthetic opioids (40).
Rural clinics and hospitals employing physicians and treatment professionals are often dispersed
across sizable geographical areas, making access to treatment difficult (42). The issue of lack of
treatment professionals in rural areas is compounded by lower salaries and fewer resources for
such physicians (43).
Buprenorphine and methadone are long-acting opioid receptor agonists utilized by
medication-assisted treatments (MATs) as potential effective options for treating opioid addictions
(27). The uneven geographic distribution of providers of MATs imposes limited access for rural
residents, along with long travel times and few options for public transportation (44). Such
obstacles can be exceptionally problematic for persons seeking MAT, which often requires
frequent and occasionally daily clinic visits (40).
Rigg et al also identified demographic and socioeconomic factors along with social factors
that contribute to geographic heterogeneity of the opioid epidemic. Socioeconomic disadvantages

may increase the risk the substance abuse, along with selective out-migration of higher educated
individuals due to employment restructuring (45). The movement of livable-wage jobs out of rural
areas has resulted in wage polarization, and has led to fewer opportunities and intensified
disproportional clustering of multigenerational economic geographic distress in rural communities
(46). Such clustering in rural communities may also result in lack on anonymity, which may cause
persons suffering from addiction to discontinue or avoid treatment altogether to avoid stigma (47).
Although stigma is not only present in rural communities, it can be more pronounced. Treatment
specialists in rural communities are more likely to be friend or family members, which further
decreases anonymity and can be a powerful deterrent to seeking out treatment (40).
Economic Burden
Unclear explanations for the geographic variation of the opioid epidemic can result in
ineffective policy implementation and intervention strategies aimed at preventing the progression
of the current opioid epidemic. The prevalence of opioid misuse and abuse has been difficult to
determine, and the consequential burden on society due to this misuse has been difficult to quantify
(48). This difficulty can be attributed to varied data collection methodologies and varied
terminologies associated with persons directly contributing to the opioid epidemic (48). The
overall burden of the opioid epidemic has been multifactorial and difficult to quantify, as it
manifests itself in numerous ways (49). The financial burden associated with opioid misuse and
abuse is particularly significant, particularly when taking into consideration factors associated with
healthcare and employers’ costs, and the cost of treatment for patients with opioid addiction (50).
Determining this total economic burden resulting from the opioid epidemic is an essential
component when identifying strategies aimed at prevention (51).

Despite discrepancies throughout findings related to the nonmedical use of opioids, the
data collected is in agreeance that the consequence of opioid misuse is significant and continually
increasing (48). Estimates of the overall cost to society – taking into account variables such as
healthcare, workplace and criminal justice system costs associated with opioid use and abuse – has
risen from $11.8 billion in 2001, to $55.7 billion in 2007, and $78.5 billion in 2013 (44, 50, 51).
A recent study was conducted in 2013 by Florence et al in order to estimate the total
economic burden caused only by prescription opioid overdose. This study maintained the
importance of understanding the distribution of the economic burden created by opioid misuse and
abuse in order to inform clinicians, researchers and government leaders; collected data is used by
government leaders and healthcare professionals when choosing cost effective methods aimed at
addressing the opioid epidemic. This study determined that the total economic burden in 2013 was
estimated to be $78.5 billion (51). This study also estimated that over one third of this estimation
was due to increase healthcare and treatment of substance abuse costs, totaling to $28.9 billion
(51).
Florence et al assessed the cost of prescription opioid overdose based on the incidence of
deaths contributed to overdose, and the prevalence of opioid abuse and dependence for the 2013
calendar year. This study also took into consideration the cost for persons experiencing overdose
or abuse and the costs imposed on society in general, including healthcare costs, the cost of
treatment for substance abuse, criminal justice costs, and lost productivity in the workplace (51).
The total estimated aggregate costs place a substantial economic burden on local, state, and federal
government (51). Although difficult to quantify all costs resulting from opioid misuse and abuse,
the costs that are identifiable assist in increasing the understanding of the impacts that this
widespread epidemic embodies.

Despite the efforts of numerous cohorts of scientists and economists, the White House
Council of Economic Advisors (CEA) has determined that previous attempts to estimate the
economic cost of the opioid crisis has been greatly underestimated. The CEA determined that while
these previous attempts at informative about certain areas of costs, they only partially account for
the damage imposed by this opioid epidemic (52). The main contributor to this underestimation
results from the undervaluing of fatalities resulting from opioid overdoses (52).
This estimate completed by the CEA adjusted for the underreporting of opioids in overdose
deaths, including those involving heroin-related deaths, which were unaccounted for in previous
studies (Florence et al) aimed at determining the economic burden of the opioid epidemic; the
nonfatal costs of opioid misuse and abuse were also accounted for by the CEA (52). The most
recent estimate completed by the CEA in 2015 put the total economic cost of the opioid epidemic
at an estimate of $504.0 billion, with a total cost estimate range from a low of $239.9 billion to a
high of $622.1 billion (52).
The CEA recognized and acknowledged the large gap between their estimate of the
economic cost of the opioid epidemic and previous estimates completed by other agencies and
cohorts. The CEA’s reasons for this disparity resulted from their full account for a value of lives
lost, the increasing number of overdose deaths in recent years, the focus of previous studies
exclusively on prescription opioids, and the adjustment of overdose deaths based on recent
research of the significant underreporting of opioid related overdose deaths (52). Estimates
completed by individual unverified agencies determining the current values of this economic
burden have continued to increase beyond the most recent value determined by the CEA.

COMBATING THE OPIOID EPIDEMIC
Current Solutions
The emergence of the opioid epidemic has been multifactorial, which makes the
development of strategies aimed at curbing this epidemic difficult. To date, most of the efforts
aimed at addressing the opioid epidemic have been focused on downstream strategies,
specifically treatment approaches for persons suffering with addiction and OUD (40).
Comparatively, less effort has been devoted to upstream strategies such as prevention and
education (40). The lack of medical education on proper opioid prescribing and addiction may
have contributed to the increased availability and use of opioids (40). Heath care providers
should provide education about the disease of addiction and the overdose risk associated with
opioids, and should provide patients with information about the dangers of mixing substances
and using higher doses than prescribed (28).
An upstream strategy aimed at detecting diversions in prescribing practices is the
prescription drug monitoring program (PDMP), which have been established in nearly every
state and aim to reduce the availability of opioids and to detect patients with multiple providers
(6). Current guidelines set by the CDC suggest the providers review PMDP data prior to the
prescribing of any opioids (53). A strategy aimed directly at reducing fatal overdoses resulting
from opioid use is the availability of naloxone, an opioid receptor antagonist (54). The
effectiveness of naloxone depends on whether overdose bystanders have easy access naloxone,
can promptly recognize correct signs and symptoms of overdose, and promptly and effectively
administer this medication (6).

CONCLUSION
The opioid epidemic, initially driven by the increased availability of prescription opioids
and heroin is now fueled by fentanyl and fentanyl analogs. These opioids act on opioid receptors,
triggering downstream effects and may result in addiction and OUD. Medication exists for the
treatment of OUD, but access to licensed providers and this medication may be limited due to
geographical characteristics, and these characteristics lead to unique barriers and societal
impacts, especially in rural America. The opioid epidemic has also caused a significant economic
burden, which influences policy implementation and intervention strategies. Current research
studies about OUD involving genetics, epigenetics, and pharmacogenetics are being conducted
in order to determine risk and susceptibility.

Prospective Research
The regional differences that exists within the opioid epidemic are interesting because a
substantial amount of variation exists. It would be interesting to conduct a longitudinal study of
the effects of opioids specifically in South Dakota, which is largely a rural state. Understanding
these geographical differences that exist in each state would be helpful in fine tuning solutions to
address the underlying social and economic factors that are a part of the modern-day opioid
epidemic.
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